Director/PDMR Shareholding

Hikma Pharmaceuticals Plc 17 December 2007 For Immediate Release 17 December 2007 Notification of transaction by a Director/PDMR LONDON, 17 December 2007 - Hikma Pharmaceuticals PLC (the 'Company') (LSE: HIK) (DIFX:HIK) announces that Mr. Samih Darwazah, Non-executive Chairman of the Company, has today notified the Company of the sale of 320,000 ordinary shares of 10 pence each in the capital of the Company, received by him pursuant to an exercise of share options in the Company on 15 October 2007. The sale was made in London at a price of 498.0 pence per share and was executed on 14 December 2007. The shares sold represented 0.187% of the outstanding share capital of the Company, and following the sale Mr Darwazah remains interested in 1,706,506 ordinary shares, representing 0.999% of the share capital of the Company. Mr. Darwazah is both a director and a Person Discharging Managerial Responsibility in respect of the Company, and the above notification relates to DTR 3.1.4R(1)(a) and other Listing Rules. -- ENDS -- Enquiries: Hikma Pharmaceuticals PLC Henry Knowles +44 20 7399 2760 Company Secretary Susan Ringdal +44 20 7399 2760 Investor Relations Director Brunswick Group Jon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: 'Branded', 'Injectables' and 'Generics'. Hikma's operations are based principally in the Middle East and North Africa ('MENA') region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2006, the Group achieved revenues of $317 million (2005 $262 million) and profit attributable to shareholders was $55 million (2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. For news and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings